Status:
RECRUITING
Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions
Lead Sponsor:
Centre Francois Baclesse
Conditions:
Undifferentiated Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The study is based on the constitution of a collection of tumor and blood samples for the development of tumoroid for functional tests to predict clinical response to treatment.
Eligibility Criteria
Inclusion
- Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation
- Patient with indication for systemic 1st-line treatment at the time of inclusion. Treatment may already have begun at the time of inclusion, but within the limit of 2 treatment cycles administered.
- Patient with life expectancy greater than 3 months
- Patient of legal age
- Patient affiliated to a social security scheme
- Signature of informed consent prior to any specific study procedure
Exclusion
- Persons deprived of their liberty or under guardianship (including curatorship)
- Pregnant or breast-feeding patient
Key Trial Info
Start Date :
March 5 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2032
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06612827
Start Date
March 5 2025
End Date
December 15 2032
Last Update
December 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre François Baclesse
Caen, France